Caldwell Trust Co Takes Position in Zoetis Inc. $ZTS

Caldwell Trust Co purchased a new stake in shares of Zoetis Inc. (NYSE:ZTS) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 12,147 shares of the company’s stock, valued at approximately $1,894,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in ZTS. Nova Wealth Management Inc. bought a new stake in shares of Zoetis during the 1st quarter valued at about $25,000. 1248 Management LLC bought a new stake in Zoetis in the first quarter worth $27,000. Saudi Central Bank bought a new position in shares of Zoetis during the first quarter valued at about $29,000. REAP Financial Group LLC increased its holdings in shares of Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after buying an additional 131 shares during the period. Finally, NewSquare Capital LLC lifted its stake in shares of Zoetis by 69.1% in the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after acquiring an additional 85 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 0.8%

Shares of Zoetis stock opened at $118.60 on Monday. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31. Zoetis Inc. has a 12-month low of $115.25 and a 12-month high of $181.85. The company has a market cap of $52.26 billion, a P/E ratio of 19.97, a PEG ratio of 2.46 and a beta of 0.97. The company’s fifty day simple moving average is $130.95 and its two-hundred day simple moving average is $145.94.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.62 by $0.08. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The firm had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.42 billion. During the same period last year, the company posted $1.58 EPS. The company’s quarterly revenue was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Tuesday, January 20th will be given a dividend of $0.53 per share. This is a boost from Zoetis’s previous quarterly dividend of $0.50. This represents a $2.12 annualized dividend and a dividend yield of 1.8%. The ex-dividend date is Tuesday, January 20th. Zoetis’s dividend payout ratio is presently 33.67%.

Wall Street Analyst Weigh In

ZTS has been the subject of several analyst reports. Argus restated a “buy” rating and set a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. BTIG Research restated a “buy” rating and issued a $160.00 target price on shares of Zoetis in a report on Wednesday, December 3rd. HSBC set a $140.00 target price on shares of Zoetis in a research note on Wednesday. KeyCorp initiated coverage on shares of Zoetis in a report on Thursday, November 20th. They issued a “sector weight” rating on the stock. Finally, Barclays began coverage on shares of Zoetis in a research report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price objective on the stock. Five analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $164.20.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.